Health Catalyst will appoint Simeon Kohl as CEO, president and director on September 14, with a $600,000 salary, a 100% Bonus target and planned 2,747,385 RSUs. The transition also moves Benjamin Albert to chief Business officer at $415,000, giving investors defined leadership, compensation and Equity terms to assess.

Key Highlights

  • Benjamin Albert will become chief business officer on September 14 with a $415,000 salary.
  • Health Catalyst’s inducement plan reserves 2,747,385 common-stock shares without stockholder approval.
  • Kohl’s planned RSU award includes 915,975 units vesting on September 4, 2027.

Kohl will become the principal executive officer, principal operating officer and a director, succeeding Benjamin Albert in those roles.

$2.75M-Share Inducement Plan

The Board plans to grant him 2,747,385 restricted stock units, including 915,975 units vesting on September 4, 2027, with the remainder vesting in eight approximately equal quarterly installments. Health Catalyst (NASDAQ: HCAT) adopted its 2026 Employment Inducement Incentive Plan on September 4 and reserved 2,747,385 common-stock shares for awards. It was adopted without stockholder approval under Rule 5635.

Albert Moves to Chief Business Officer

The Board accepted Albert’s resignation as CEO, president, principal executive officer, principal operating officer and director effective September 13. Health Catalyst appointed him chief business officer effective September 14, and his new salary will be $415,000. Albert will remain a Tier 2 Executive under the Executive Severance Plan. Beginning January 1, 2027, his annual bonus target will equal 60% of his base salary. The company said his resignation did not result from disagreement over operations, policies or practices. The Board expects Kohl to enter a standard indemnification agreement. Health Catalyst said Kohl has no appointment-related arrangements with another person, no reportable material transaction interest and no family relationship with its directors or executive officers.